CM
AKBA icon

Caption Management’s Akebia Therapeutics AKBA Stock Holding History

Caption Management’s Portfolio AKBA Stock Details AKBA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-1,097,400
Closed -$790K – 1403
2022
Q1 		$790K Buy
1,097,400
+497,600
+83% +$1.06M 0.01% 1036
2021
Q4 		$1.35M Buy
+599,800
New +$1.64M 0.02% 927

Other funds holding AKBA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Caption Management's AKBA Position: Q1 2026 in Review

Caption Management held its Akebia Therapeutics (AKBA) position steady in Q1 2026 at 24,692 shares worth $34.3K. The position accounts for ﹤0.01% of the portfolio, ranked #1435.

Caption Management first reported a position in AKBA in Q1 2019 and has held it in 9 quarters since. The position peaked at $678K in Q2 2020. 171 funds tracked by Wall St. Rank hold AKBA as of Q1 2026.

  • Caption Management held 24,692 shares of Akebia Therapeutics worth $34.3K as of Q1 2026.
  • Caption Management left its Akebia Therapeutics share count unchanged in Q1 2026.
  • Akebia Therapeutics made up ﹤0.01% of Caption Management's portfolio in Q1 2026, its #1435 holding.
  • Caption Management first reported a position in Akebia Therapeutics in Q1 2019 and has held it in 9 quarters since.
  • Caption Management's Akebia Therapeutics position peaked at $678K in Q2 2020.
  • 171 funds tracked by Wall St. Rank held Akebia Therapeutics as of Q1 2026.

Based on Caption Management's 13F filing for Q1 2026, filed 15 May 2026.